Gene Review:
Vipr1 - vasoactive intestinal peptide receptor 1
Mus musculus
Synonyms:
AV071699, PACAP type II receptor, PACAP-R-2, PACAP-R2, Pituitary adenylate cyclase-activating polypeptide type II receptor, ...
- VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Kojima, M., Ito, T., Oono, T., Hisano, T., Igarashi, H., Arita, Y., Kawabe, K., Coy, D.H., Jensen, R.T., Nawata, H. Pancreas (2005)
- Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Zia, H., Hida, T., Jakowlew, S., Birrer, M., Gozes, Y., Reubi, J.C., Fridkin, M., Gozes, I., Moody, T.W. Cancer Res. (1996)
- T cell vasoactive intestinal peptide receptor subtype expression differs between granulomas and spleen of schistosome-infected mice. Metwali, A., Elliott, D., Blum, A.M., Li, J., Sandor, M., Weinstock, J.V. J. Immunol. (1996)
- Neuronal release of vasoactive intestinal peptide is important to astrocytic protection of neurons from glutamate toxicity. Brown, D.R. Mol. Cell. Neurosci. (2000)
- Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Ishihara, T., Shigemoto, R., Mori, K., Takahashi, K., Nagata, S. Neuron (1992)
- Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells. Jabrane-Ferrat, N., Bloom, D., Wu, A., Li, L., Lo, D., Sreedharan, S.P., Turck, C.W., Goetzl, A.E. FASEB J. (1999)
- Genomic organization and chromosomal location of the mouse vasoactive intestinal polypeptide 1 (VPAC1) receptor. Hashimoto, H., Nishino, A., Shintani, N., Hagihara, N., Copeland, N.G., Jenkins, N.A., Yamamoto, K., Matsuda, T., Ishihara, T., Nagata, S., Baba, A. Genomics (1999)
- Differential expression of vasoactive intestinal polypeptide receptor 1 and 2 mRNA in murine intestinal T lymphocyte subtypes. Qian, B.F., Hammarström, M.L., Danielsson, A. J. Neuroendocrinol. (2001)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. Delgado, M., Ganea, D. J. Immunol. (2000)
- Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents. Fizanne, L., Sigaudo-Roussel, D., Saumet, J.L., Fromy, B. J. Physiol. (Lond.) (2004)
- Excitatory actions of vasoactive intestinal peptide on mouse thalamocortical neurons are mediated by VPAC2 receptors. Lee, S.H., Cox, C.L. J. Neurophysiol. (2006)
- Pituitary adenylate cyclase-activating polypeptide inhibits cutaneous immune function. Kodali, S., Friedman, I., Ding, W., Seiffert, K., Wagner, J.A., Granstein, R.D. Eur. J. Immunol. (2003)
- Serotonin and vasoactive intestinal peptide antagonists attenuate rotavirus diarrhoea. Kordasti, S., Sjövall, H., Lundgren, O., Svensson, L. Gut (2004)
- VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Delgado, M., Reduta, A., Sharma, V., Ganea, D. J. Leukoc. Biol. (2004)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. Delgado, M., Leceta, J., Ganea, D. J. Leukoc. Biol. (2003)
- Role of sulfhydryl groups in the binding of vasoactive intestinal peptide to its receptor on murine lymphocytes. Ottaway, C.A. J. Neuroimmunol. (1992)
- Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Leceta, J., Gomariz, R.P., Martinez, C., Abad, C., Ganea, D., Delgado, M. Ann. N. Y. Acad. Sci. (2000)
- Pituitary adenylate cyclase-activating polypeptide induces cAMP production independently from vasoactive intestinal polypeptide in osteoblast-like cells. Suzuki, A., Kotoyori, J., Oiso, Y., Kozawa, O. Cell. Signal. (1994)
- Characterisation of the Mouse Vasoactive Intestinal Peptide Receptor Type 2 Gene, Vipr2, and Identification of a Polymorphic LINE-1-like Sequence That Confers Altered Promoter Activity. Steel, G., Lutz, E.M. J. Neuroendocrinol. (2007)
- (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. Moody, T.W., Jensen, R.T., Fridkin, M., Gozes, I. J. Mol. Neurosci. (2002)
- Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Kaltreider, H.B., Ichikawa, S., Byrd, P.K., Ingram, D.A., Kishiyama, J.L., Sreedharan, S.P., Warnock, M.L., Beck, J.M., Goetzl, E.J. Am. J. Respir. Cell Mol. Biol. (1997)
- Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. Delgado, M., Munoz-Elias, E.J., Gomariz, R.P., Ganea, D. J. Immunol. (1999)
- Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1. Balster, D.A., O'Dorisio, M.S., Albers, A.R., Park, S.K., Qualman, S.J. Regul. Pept. (2002)
- Pre-clinical study on tumor vasoactive intestinal peptide receptor scintigraphy. Wang, X., Zhang, M., Yang, Z., Lin, B., Zhang, Q. Zhonghua Zhong Liu Za Zhi (2002)